Home » Stocks » Ovid Therapeutics

Ovid Therapeutics Inc. (OVID)

Stock Price: $5.37 USD 0.14 (2.68%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
After-hours: $5.38 +0.01 (0.19%) Oct 22, 6:03 PM

Stock Price Chart

Key Info

Market Cap 340.10M
Revenue (ttm) n/a
Net Income (ttm) -76.19M
Shares Out 63.33M
EPS (ttm) -1.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $5.37
Previous Close $5.23
Change ($) 0.14
Change (%) 2.68%
Day's Open 5.27
Day's Range 5.23 - 5.42
Day's Volume 336,572
52-Week Range 1.80 - 9.40

More Stats

Market Cap 340.10M
Enterprise Value 298.84M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 63.33M
Float 38.36M
EPS (basic) -1.54
EPS (diluted) -1.54
FCF / Share -1.12
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 4.24M
Short Ratio 5.95
Short % of Float 11.04%
Beta 1.88
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 11.47
Revenue n/a
Operating Income -77.47M
Net Income -76.19M
Free Cash Flow -62.10M
Net Cash 41.25M
Net Cash / Share 0.65
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -96.58%
ROE -200.70%
ROIC -877.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (7)

Buy 7
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$14.83*
(176.16% upside)
Low
10.0
Current: $5.37
High
21.0
Target: 14.83
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015
Revenue-----
Operating Income-61.41-52.93-65.01-22.54-13.19
Net Income-60.46-51.98-64.81-22.41-13.16
Shares Outstanding39.2224.6319.349.849.70
Earnings Per Share-1.54-2.11-3.35-2.28-1.36
Operating Cash Flow-51.09-45.56-31.47-17.80-5.49
Capital Expenditures-0.06-0.03-0.04-0.03-0.03
Free Cash Flow-51.15-45.59-31.51-17.83-5.52
Cash & Equivalents76.7441.5087.1351.9469.94
Net Cash / Debt76.7441.5087.1351.9469.94
Assets80.8447.6589.4653.0370.38
Liabilities10.828.846.023.732.31
Book Value70.0238.8183.4449.2968.07
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Ovid Therapeutics Inc.
Country United States
Employees 60
CEO Jeremy Max Levin

Stock Information

Ticker Symbol OVID
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: OVID
IPO Date May 5, 2017

Description

Ovid Therapeutics, a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase III clinical trial for the treatment of angelman syndrome in adults; and completed Phase II clinical trial for the treatment of fragile X syndrome in adolescent and young male adults. It is also developing OV935, a drug candidate, which is in a Phase II clinical trial for the treatment of cyclin-dependent kinase-like 5 deficiency disorder and dravet syndrome. In addition, the company undertakes research programs exploring OV329 in infantile spasm/rare epilepsies; and OV881 as a microRNA gene therapy for the treatment of angelman syndrome. Ovid Therapeutics Inc. has a collaboration agreement with Takeda Pharmaceutical Company Limited; a license agreement with H. Lundbeck A/S; strategic research collaboration with Columbia University Irving Medical Center; and license agreement with Angelini Pharma to develop, manufacture and commercialize OV101 for the treatment of angelman syndrome in Europe. The company was founded in 2014 and is headquartered in New York, New York.